BBL
KNSA icon

Beck Bode LLC’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Beck Bode LLC’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$4K – 191
2021
Q2 		$4K Buy
+300
New +$4.56K ﹤0.01% 277
2020
Q4 		– Sell
-300
Closed -$5K – 151
2020
Q3 		$5K Buy
+300
New +$5.63K ﹤0.01% 252

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Beck Bode LLC's KNSA Position: Q3 2021 in Review

Beck Bode LLC sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2021, closing a stake of 300 shares — an estimated $4K sold.

Beck Bode LLC first reported a position in KNSA in Q3 2020 and held it in 2 quarters. The position peaked at $5K in Q3 2020. 101 funds tracked by Wall St. Rank hold KNSA as of Q3 2021.

  • Beck Bode LLC reported no remaining Kiniksa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Beck Bode LLC sold 300 Kiniksa Pharmaceuticals shares in Q3 2021, an estimated $4K.
  • Beck Bode LLC first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Beck Bode LLC's Kiniksa Pharmaceuticals position peaked at $5K in Q3 2020.
  • 101 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2021.

Based on Beck Bode LLC's 13F filing for Q3 2021, filed 22 Oct 2021.